CoV2 Paired Antibody
2 vials of sterile filtered clear colorless solution.
Greater than 90%.
Description
SARS CoV2 antibodies, coating C865 and conjugating C866 which target CoV2 nucleoprotein. SARS CoV2 antibodies, coating and conjugating are paired for the preparation of CoV2 antigen rapid test for the detection of CoV-2 nucleoprotein. SARS CoV2 antibodies, coating and conjugating do not cross-react with CoV nucleoproteins: 229E, HKU1, NL63 and OC43.
CoV2 antigen rapid test prepared by SARS CoV2 antibodies, coating and conjugating can detect 5ng/ml of recombinant SARS-CoV2 nucleoprotein.
Please note that when ordering for example: 100µg antibody we ship 50µg from each of the antibodies (100µg in total).
Product Specs
The SARS Coronavirus, an enveloped virus, possesses three key outer structural proteins: membrane (M), envelope (E), and spike (S) proteins. The spike (S) glycoprotein plays a crucial role in virus infection by interacting with a cellular receptor to facilitate membrane fusion, enabling the virus to enter susceptible target cells. Due to its involvement in the viral entry process, the S-protein is a primary target for neutralizing antibodies. Studies have confirmed that SARS is caused by a human coronavirus, a major contributor to upper respiratory tract illnesses like the common cold. These coronaviruses, classified as positive-stranded RNA viruses, possess the largest known viral RNA genomes (27-31 kb). The infection process begins with the binding of the viral spike protein, a 139-kDa protein, to specific receptors on host cells. Being the main surface antigen of the coronavirus, the spike protein is critical for this interaction. Notably, a 46 kDa nucleocapsid protein is prominently observed in culture supernatants infected with the SARS virus, suggesting its potential as a significant immunogen for early diagnostic applications.
This product consists of a pair of SARS CoV2 antibodies: a coating antibody (C865) and a conjugating antibody (C866), both targeting the CoV2 nucleoprotein. Designed specifically for the development of CoV2 antigen rapid tests, these antibodies facilitate the detection of CoV-2 nucleoprotein. Notably, they exhibit high specificity and do not cross-react with CoV nucleoproteins from 229E, HKU1, NL63, or OC43. CoV2 antigen rapid tests prepared using this antibody pair demonstrate a detection sensitivity of 5ng/ml for recombinant SARS-CoV2 nucleoprotein.
It is important to note that when ordering a specific quantity, for instance, 100µg of antibody, the shipment will contain 50µg of each antibody, totaling 100µg.
Greater than 90%.
The product is provided as two vials containing sterile filtered, clear, and colorless solutions.
The antibodies are formulated in phosphate-buffered saline (PBS) at a pH of 7.4.
While the SARS CoV2 antibodies, both coating and conjugating, remain stable at 4°C for up to one week, storage at or below -18°C is recommended. For long-term storage, adding a carrier protein such as 0.1% HSA or BSA is advisable. To maintain optimal antibody performance, avoid repeated freeze-thaw cycles.
These antibodies are specifically developed and validated for use in lateral flow rapid test applications.
Purified monoclonal IgG by protein A chromatography.
Mouse antibody Monoclonal.
Product Science Overview
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global health crisis. The development of effective therapeutics and vaccines has been a priority. Among the various strategies, monoclonal antibodies (mAbs) have shown promise in neutralizing the virus and preventing infection. Mouse anti-SARS-CoV-2 paired antibodies are a significant area of research in this context.
Mouse anti-SARS-CoV-2 antibodies are typically generated by immunizing mice with SARS-CoV-2 antigens, such as the spike protein or its receptor-binding domain (RBD). The immune response in mice leads to the production of antibodies that can specifically bind to these antigens. Hybridoma technology is often used to produce monoclonal antibodies from the immunized mice. This involves fusing antibody-producing B cells from the mice with myeloma cells to create hybrid cells that can be cultured to produce large quantities of the desired antibodies .
The generated antibodies are then characterized for their binding affinity, specificity, and neutralizing capability. One study described the generation of a panel of murine mAbs directed against the RBD of SARS-CoV-2. Among these, one antibody, 2B04, demonstrated remarkable potency in neutralizing the virus in vitro with a half-maximal inhibitory concentration (IC50) of less than 2 ng/ml . In a murine model of SARS-CoV-2 infection, 2B04 protected the challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination .
Mouse anti-SARS-CoV-2 paired antibodies are valuable tools in both research and therapeutic applications. In research, they are used to study the virus’s mechanisms of infection and to develop diagnostic assays. In therapeutics, these antibodies can be used as a form of passive immunization to provide immediate protection against the virus. They are also being explored as potential treatments for COVID-19, either alone or in combination with other antiviral agents .
While mouse anti-SARS-CoV-2 antibodies have shown promise, there are challenges associated with their use. One major challenge is the potential for immunogenicity when used in humans, as mouse antibodies can be recognized as foreign by the human immune system. To address this, humanization techniques are employed to modify the mouse antibodies to be more similar to human antibodies. Additionally, ongoing research is focused on improving the efficacy and stability of these antibodies to enhance their therapeutic potential .
In conclusion, mouse anti-SARS-CoV-2 paired antibodies represent a crucial area of research in the fight against COVID-19. Their ability to neutralize the virus and provide protection in animal models highlights their potential as both research tools and therapeutic agents. Continued advancements in this field will be essential for developing effective interventions against SARS-CoV-2 and future emerging pathogens.
